Charles River Laboratories has completed the previously announced acquisition of MPI Research for approximately $800 million in cash, subject to certain customary adjustments.
MPI is a non-clinical contract research organization (CRO) providing testing services to biopharmaceutical and medical device companies worldwide. Acquiring MPI will augment Charles River’s position as a global early-stage CRO by strengthening its ability to partner with clients across the drug discovery and development continuum.
“We are pleased to welcome the exceptional team at MPI Research to the Charles River family. The addition of MPI’s scientific expertise, high-quality services, and complementary capabilities will enable us to enhance the support we can provide to clients, as they address the complex challenges of drug discovery and early-stage development,” James C. Foster, Chairman and Chief Executive Officer of Charles River Laboratories, said. “The acquisition of MPI also enhances our ability to achieve our long-term growth goals by building scale to meet current and future demand, and by expanding our biotechnology client base, the fastest-growing market segment.”